Actionable news
All posts from Actionable news
Actionable news in OCLS: Oculus Innovative Sciences, Inc.,

Oculus Innovative: Investor Presentation At Dawson James Investor Conference

The following excerpt is from the company's SEC filing.

Exhibit 99.1

Investor Presentation At Dawson James Investor Conference October 15, 2015 (NASDAQ: OCLS & OCLSW)

This presentation includes forward - looking statements that are made pursuant to the “safe harbor ” provisions of the Private Securities Litigation Reform Act of 1995 . While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers and listeners are cautioned that such forward - looking statements represent management's opinion . Whereas management believes such representation to be true and accurate, based on informatio n and data available to the company at this time, actual results may differ materially from those described . The company's operations and business prospects are always subject to risk and uncertainties . Important factors that may cause actual results to differ are set forth in the company’s periodic filings with the US Securities and Exchange Commission . Page | 2 Oculus Innovative Sciences, Inc. Forward Looking Statement

Corporate Overview & Investment Summary Page | 3 Oculus Innovative Sciences, Inc. Oculus is a specialty pharmaceutical company, focused on developing and selling unique, affordable & branded products for dermatology and advanced tissue care 11 510(k)s and 10 CE marks cleared Microcyn - based products, commercially established in over 35 countries ― Fiscal year 2015 revenue of $14 million from sales of Microcyn - based products via direct sales force in the U.S. and strategic business partnerships in Mexico, Europe, the Middle East and Asia Versatile Core Hypochlorous Acid (“HOCI”) based Microcyn ® technology has the potential to address a number of dermatological conditions 45 issued patents & 82 pending – Issued U.S. patent for HOCl on atopic dermatitis Investment Opportunity: Low Value & High Revenue Growth as a Turnaround: Market cap of $20 million vs $8.8M cash (6/30/15), $14M revenue & no debt Double digit product revenue growth, led by dermatology

2014 – Year of Transformation - after Ruthigen IPO Strengths: Strong and growing international revenue base Versatile and effective Microcyn technology Valuable position in Ruthigen Challenges: With Ruthigen IPO, lost founding CEO and most of Board Declining revenues and lost major animal health care business Relied on flawed partnership business model – “mile wide & inch deep” And without a clear plan for growth Actions: Appointed a new CEO and reconstituted the Board adding great experience After an intensive strategic analysis with the Board, developed the following strategy and plan.

Solution: New Board, New Strategy & New Leadership Core Market: Grow Dermatology Business with Direct Sales Force in U.S. Step 1 : Build a direct sales force platform , using Microcyn as initial cornerstone with pipeline of unique, affordable & branded products Diversify into non - HOCI technologies via license, becoming a multiple technology, dermatology company. Use international distribution network to grow international dermatology Step 2: Identify Orphan Drugs and/or low cost NDAs to develop for our direct sales force to sell Non - Core markets: All other markets in US and all markets OUS Use partnership model to generate cash for the growth of the derm business Transformational strategy, moving from partnering, to direct sales, with derm as our core market, should provide consistent revenue growth.

Fall to Late 2014: Crafted a very detailed 3 year action and financial plan, blessed by the New Board Hired very talented, derm sales & marketing, management team; over 70+ experience Hired 10 experienced field sales people ― Located in high volume regions based on IMS data Set up national wholesaler distribution with Cardinal, McKesson, Ams . Ber ., HD Smith L aunched Alevicyn Gel, Alevicyn Dermal Spray and Celacyn Scar treatment Results: Sold 1,339, 4,374 & 7,028 units in consecutive December thru June QTRs Year to date – 2015: - Strong cash position of $8.8 million as of June 30, 2015 Licensed & filed 510k for new patented skin repair and other technologies for future pipeline Received FDA clearance for new “no touch” spray gel in June & launched in late August Implemented periodic price increases but remaining the low cost provider Loaded 2 new products in late September and launch in October/...